Oxytocin vs PT-141
Updated 7 sources
Key differences
- 1PT-141 acts on melanocortin (MC4R) receptors and drives desire and arousal; oxytocin acts on oxytocin receptors and shapes bonding and the after-orgasm feeling.
- 2In trials, nasal oxytocin did not change drive, arousal or erection, and in women with sexual dysfunction it did no better than placebo. Guides call PT-141 the stronger libido tool.
- 3PT-141 is injected hours before sex; oxytocin is sprayed 30 to 45 minutes before.
Side by side
Facts from each record, in the same words as their own pages.
| Oxytocin | PT-141 | |
|---|---|---|
| Category |
|
|
| Evidence |
|
|
| FDA status |
|
|
| WADA |
|
|
| Half-life |
|
|
| Routes |
|
|
| Forms |
|
|
| Reported doses |
|
|
| Most cited frequency |
|
|
| Vial sizes |
|
|
| Mixed vial keeps |
|
|
| Protocols on file |
|
|
Doses shown are what sources report, labelled by origin. Not medical advice.
Read each in full
Sources
7 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.
Clinical study2
- Differential effects of intranasal oxytocin on sexual experiences and partner interactions in couples (Horm Behav 2014)PubMed · checked Oct 24, 2026
- Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial (Fertil Steril 2015)PubMed · checked Oct 24, 2026
Regulatory5
- Pitocin (oxytocin injection, USP) label (SPL v15, effective 2026-05-05)DailyMed · checked Oct 24, 2026
- Vyleesi (bremelanotide) prescribing information, 2019FDA · checked Oct 23, 2026
- Drugs@FDA: NDA 018261 PitocinFDA · checked Oct 24, 2026
- Drugs@FDA: NDA 012285 Syntocinon nasal solutionFDA · checked Oct 24, 2026